Table 1.

Baseline characteristics of 8 ESRD patients with hemophilia

Patient #	1	2	3	4	5	6	7	8
Gender	M	M	M	M	M	M	M	M
Dialysis age	44	28	31	55	67	59	56	61
Causes of renal failure	HCV-GN	Obstruction	GN	DN	DN, ATN	DN	Ectopic kidney, Obstruction, NS	DN
Hemophilia type	Severe HHA	Severe HHA	Mild HHA	Moderate HHA	AHA	Severe HHA	Severe HHA	AHA
Other comorbidity	HCV, THPT	Acute myelitis, HTN	HTN, HCV (cured)	HTN	AF, HF	HCV	HTN, HF	CG, HTN
ESRD complication	Overload	data unavailable	Overload, Uremia, HF	None	Overload, HF	Overload HK	Overload, HF	Uremia
Known CKD duration	4 yr	2 yr	10 yr	5 yr	9 yr	5 yr	2 wka	4 yr
Urea (mmol/l)	20.7	56.6	37.6	29.2	28.0	36.2	37.6	41.2
SCr (μmol/l)	1592	2153	1283	645	600	868	946	743
HD before PD	3 mo	<2 wk	None	None	None	None	< 2 wk	None
Notable concurrent treatmentsb	None	None	None	Vitrectomy	Bortezomib	None	None	Rituximab+ bortezomib

AHA, acquired hemophilia type A; CG, cryoglobulinemia; dx, diagnosis; DN, diabetic nephropathy; GN, glomerulonephritis; HCV, hepatitis C virus; HD, hemodialysis or continue renal replacement therapy; HF, heart failure; HK, hyperkalemia; HHA, hereditary hemophilia type A; HTN, hypertension; M, male; NS, nephrotic syndrome; PD, peritoneal dialysis; THPT, tertiary hyperparathyroidism.

^aThe judgment of chronic nature of the patient’s kidney disease was based on bilateral renal atrophy.

^bRefers to important treatment within 2 weeks after catheter placement.